Biodexa Pharmaceuticals Plc

BDRX

US59564R7089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			Pre-market 08:20:36 am
1.08 ^USD	+51.88%		1.015	-6.02%

Jul. 11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Jul. 11	Sector Update: Health Care	MT

Biodexa Pharmaceuticals plc Announces Departure of Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer

July 05, 2024 at 05:25 pm EDT

Biodexa Pharmaceuticals Plc announced effective July 4, 2024, Dmitry Zamoryakhin, chief scientific officer and chief medical officer of the company departed the company.

Latest news about Biodexa Pharmaceuticals Plc

Sector Update: Health Care Stocks Rise Late Afternoon	Jul. 11	MT
Sector Update: Health Care	Jul. 11	MT
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	Jul. 11	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	Jul. 11	MT
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar	Jul. 11	MT
Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data	Jul. 11	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 10	MT
Biodexa Pharmaceuticals plc Announces Departure of Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer	Jul. 05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 03	MT
Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024	Jul. 02	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Jul. 01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	Jun. 28	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	Jun. 27	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Jun. 24	MT
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa? At 12 Months in Familial Adenomatous Polyposis	Jun. 24	CI
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	Jun. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	Jun. 11	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jun. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Jun. 04	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	Jun. 03	MT
Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis	Jun. 03	CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	May. 31	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	May. 30	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	May. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	May. 24	MT

Chart Biodexa Pharmaceuticals Plc

Duration

Period

More charts

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Sector

Biotechnology & Medical Research

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8362 GBP

Average target price

6.257 GBP

Spread / Average Target

+648.30%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIODEXA PHARMACEUTICALS PLC	-59.70%	10.4M
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B
REGENERON PHARMACEUTICALS, INC.	+23.00%	117B
ARGENX SE	+25.68%	27.77B
BIONTECH SE	-19.75%	20.44B
GENMAB A/S	-14.83%	16.62B
BEIGENE, LTD.	-16.56%	15.92B
WUXI APPTEC CO., LTD.	-46.65%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs